Functional Genomics Identifies Potential Therapeutic Targets for Clear Cell Renal Cell Carcinoma

By Reuters Staff

July 21, 2014

NEW YORK (Reuters Health) - Functional genomics has identified 31 potential therapeutic targets that contribute to clear cell renal cell carcinoma (ccRCC) proliferation, researchers report.

The clear cell subtype accounts for about 80% of all RCC cases, and up to 30% of patients present with metastatic disease. As many as 30% of patients who undergo partial or total nephrectomy also develop metastatic disease within 5 years of the original diagnosis.

Dr. John A. Copland from Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida and colleagues used a high-throughput gene microarray screen to identify genetic transcripts that are overexpressed at all stages of ccRCC (compared with matched normal kidney tissue).

With this approach, they identified 31 genes that are required for ccRCC cell propagation, including one gene (CDH13) that plays a role in tumor angiogenesis and four novel factors (KISS1R, KSR1, CAMK1, and SSPN) that play a pro-migratory role in ccRCC, according to the June 12 Oncotarget online report.

"In addition to the potential of these genes and gene products to help us design new drugs, they could also serve as biomarkers for accurate diagnosis," lead author Christina von Roemeling said in a related news release. "It really is a treasure trove for future research on kidney cancer."

In the same news release, Dr. Copland said, "We are releasing these discoveries to the scientific community so that a large effort can be mounted to find out more about these genes and how they can be effectively targeted. We owe patients speedy research that focuses on new treatments to save lives."

Dr. Copland did not respond to a request for comments.


Oncotarget 2014.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: